Immune Checkpoint Myocarditis from Adjuvant Treatment of Melanoma

Author Info

John Dasher Lavanya Kondapalli Carrie Lenneman

Corresponding Author

Carrie Lenneman
Division of Cardiology, Department of Medicine, University of Alabama, Birmingham, Alabama, USA

A B S T R A C T

Immune checkpoint inhibitors (ICIs) are effective therapy for many metastatic cancers and are now being used as adjuvant treatment for many stage III cancers to reduce the high risk of reoccurrence. ICIs activate a patient’s own T-cells to fight cancer, but in some cases, immune-related adverse events (irAEs) with inflammation of many organs can occur. Rare cases of myocarditis have been reported. More data is needed to improve our ability to monitor, diagnose and treat irAEs.

Article Info

Article Type

Case Report

Publication history

Received: Wed 28, Oct 2020
Accepted: Fri 20, Nov 2020
Published: Thu 31, Dec 2020

Copyright

© 2023 Carrie Lenneman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.GCCR.2020.01.05